Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sara Asimus (Mölndal, Sweden), Mats Någård, Rikard Pehrson, Sara Asimus, Tove Hegelund, Paul Jansson, Naimish Patel. Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD. Eur Respir J 2015; 46: Suppl. 59, 3950

Member's Comments

No comment yet.

Related content which might interest you: CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624 Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Comparing the effects of orally and intranasally administered IKK2 inhibitors in a 4 day tobacco-smoke exposed model of COPD Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Efficacy of dexamethasone, roflumilast and azithromycin in a murine cigarette smoke/NTHi infection model Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation Source: International Congress 2016 – Airway response to infection Year: 2016 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013